First Nebraska Trust Co Makes New $2.97 Million Investment in Pfizer Inc. $PFE

First Nebraska Trust Co purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 104,083 shares of the biopharmaceutical company’s stock, valued at approximately $2,968,000.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its stake in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after buying an additional 31,412,883 shares during the period. State Street Corp increased its stake in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after buying an additional 5,501,032 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Pfizer by 11.1% during the first quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after buying an additional 5,364,929 shares during the period. Bank of America Corp DE purchased a new position in shares of Pfizer during the second quarter valued at $1,049,602,000. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock valued at $1,022,606,000 after acquiring an additional 293,029 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 2.3%

PFE opened at $29.98 on Wednesday. The firm has a market cap of $170.85 billion, a price-to-earnings ratio of 39.44, a PEG ratio of 2.08 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $23.62 and a 12 month high of $31.06. The stock has a fifty day moving average price of $28.64 and a 200-day moving average price of $26.84.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the prior year, the business posted $0.87 EPS. The firm’s quarterly revenue was down .4% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.7%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 226.32%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Scotiabank raised their target price on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Tuesday, October 6th. HSBC boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Cantor Fitzgerald upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $28.65.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat earnings and revenue expectations, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its full-year revenue guidance to $62 billion–$64 billion, citing strong performance and momentum in newer and acquired medicines. Pfizer lifts FY26 guidance
• Positive Sentiment: Growth is broadening beyond COVID products: launched and acquired medicines grew 32%, with Eliquis, Padcev, Vyndaqel, Nurtec and Lorbrena among the products highlighted. Pfizer also cited progress in its obesity and oncology programs. Pfizer’s product growth
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. Her experience may support continuity in financial planning and capital allocation, though the appointment alone does not change the company’s outlook. Pfizer appoints Cecile Guegan CFO
• Negative Sentiment: Quarterly revenue was essentially flat year over year as COVID-related demand continued to fall: Paxlovid sales dropped 63% and Comirnaty sales declined 29%. The ongoing transition away from pandemic products leaves investors focused on whether newer medicines can offset those declines. Pfizer Q3 product sales
• Negative Sentiment: Despite the earnings beat and raised guidance, the stock eased. Investor caution may reflect expectations already embedded in the shares and uncertainty about the longer-term payoff from Pfizer’s acquisitions, pipeline and efforts to address upcoming patent expirations. Pfizer’s growth test ahead

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.